Instadose Pharma Corp. (INSD) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Instadose Pharma Corp. (INSD) trades at $0.0001 with AI Score 44/100 (Grade C). Instadose Pharma Corp. focuses on the cultivation, processing, and global distribution of medical-grade cannabinoid oil. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for INSD: INSD does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates INSD against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
INSD: the 3 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Instadose Pharma Corp. (INSD) Healthcare & Pipeline Overview
Instadose Pharma Corp. cultivates, processes, and distributes medical-grade cannabinoid oil globally, operating within the specialty and generic drug manufacturing sector. The company faces significant competition and regulatory hurdles in the evolving cannabis market, with a focus on establishing reliable supply chains.
What Is the Investment Thesis for INSD?
Instadose Pharma Corp. presents a high-risk, high-reward investment opportunity within the rapidly evolving medical cannabis sector. The company's focus on medical-grade cannabinoid oil positions it to capitalize on the increasing acceptance and legalization of cannabis for medicinal purposes. However, the company's small size and limited resources, indicated by its market capitalization of $0.00B and only two employees, pose significant challenges. Key value drivers include securing regulatory approvals in key markets, establishing reliable supply chains, and forming strategic partnerships with pharmaceutical companies. Growth catalysts include the expansion of medical cannabis legalization globally and the development of new cannabinoid-based therapies. Potential risks include intense competition from established players, fluctuating cannabinoid prices, and evolving regulatory frameworks.
Based on FMP financials and quantitative analysis
INSD Key Highlights
Market Cap of $0.00B indicates a micro-cap company with high growth potential but also significant risk.
- P/E ratio of -0.01 suggests the company is not currently profitable.
- Beta of -401.63 indicates extreme volatility and a negative correlation with the market.
- The company's focus on medical-grade cannabinoid oil aligns with the growing demand for cannabis-based therapies.
- Based in Canada, Instadose Pharma benefits from a relatively progressive regulatory environment for cannabis.
Who Are INSD's Competitors?
INSD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| MNNGF Baijin Life Science Holdings Limited | $0.08 | +0.00% | $74.6M | 63 |
| SHIEF Shield Therapeutics plc | $0.07 | +0.00% | $75.3M | 62 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are INSD's Key Strengths?
Focus on medical-grade cannabinoid oil.
- Potential for early mover advantage in emerging markets.
- Strategic location in Canada with established cannabis regulations.
What Are INSD's Weaknesses?
Small size and limited resources.
- Dependence on regulatory approvals.
- Limited brand recognition.
What Could Drive INSD Stock Higher?
Potential regulatory approvals in new geographic markets could drive revenue growth.
- Expansion of the medical cannabis market globally is creating new opportunities.
- Strategic partnerships with pharmaceutical companies could lead to new product development and commercialization.
What Are the Key Risks for INSD?
Financial-distress signal — its Altman Z-Score of -5.65 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Intense competition from established players could limit market share.
- Fluctuating cannabinoid prices could impact profitability.
- Evolving regulatory frameworks could create uncertainty and increase compliance costs.
- Limited financial resources may hinder growth and expansion.
- Dependence on a small number of customers could create vulnerability.
What Are the Growth Opportunities for INSD?
- Expansion into new geographic markets: The global medical cannabis market is expanding rapidly, presenting significant opportunities for Instadose Pharma to enter new markets. Focusing on countries with favorable regulatory environments and unmet medical needs could drive revenue growth. For example, expansion into Europe or South America could significantly increase the company's market reach. This expansion requires navigating complex regulatory landscapes and establishing strategic partnerships with local distributors. Timeline: 2-3 years.
- Development of new cannabinoid-based therapies: Investing in research and development to create new cannabinoid-based therapies could create new revenue streams and differentiate Instadose Pharma from its competitors. Focusing on specific therapeutic areas, such as pain management or epilepsy, could attract partnerships with pharmaceutical companies and drive long-term growth. This requires significant investment in research and clinical trials. Timeline: 3-5 years.
- Strategic partnerships with pharmaceutical companies: Collaborating with established pharmaceutical companies to develop and commercialize cannabinoid-based products could provide access to capital, expertise, and distribution networks. This could accelerate the development and commercialization of new therapies and increase market share. Identifying and securing partnerships with companies interested in expanding their product portfolios into the medical cannabis space is crucial. Timeline: 1-2 years.
- Securing regulatory approvals in key markets: Obtaining regulatory approvals for its products in key markets, such as the United States and Europe, is essential for expanding its market reach and increasing revenue. This requires navigating complex regulatory processes and demonstrating product safety and efficacy. Investing in regulatory compliance and building relationships with regulatory agencies is critical. Timeline: Ongoing.
- Establishing a reliable supply chain: Ensuring a consistent and high-quality supply of cannabinoid oil is crucial for meeting customer demand and maintaining product quality. Investing in cultivation infrastructure, processing facilities, and quality control measures is essential for building a reliable supply chain. This requires careful planning and execution to ensure compliance with regulatory standards and efficient operations. Timeline: Ongoing.
What Are INSD's Competitive Advantages?
- Focus on medical-grade cannabinoid oil provides a degree of differentiation.
- Early mover advantage in establishing relationships with pharmaceutical companies (potential).
- Proprietary cultivation and extraction techniques (if any, not specified in data).
What Does INSD Do?
Instadose Pharma Corp., established in 2017, is a Canadian company focused on the production and distribution of medical-grade cannabinoid oil. The company's operations encompass the entire value chain, from growing and cultivation to processing and global distribution. Instadose Pharma aims to supply pharmaceutical companies and researchers with high-quality cannabinoid oil for various medical applications. Based in Burlington, Canada, the company is strategically positioned to serve both domestic and international markets. The company's core business revolves around cultivating various strains of cannabis, extracting cannabinoid oils, and ensuring product quality through rigorous testing and adherence to regulatory standards. Instadose Pharma's success hinges on its ability to navigate the complex regulatory landscape governing the production and distribution of medical cannabis, while also establishing strong relationships with key players in the pharmaceutical industry. The company's long-term vision involves expanding its product portfolio and geographic reach to become a leading global supplier of medical-grade cannabinoid oil. With only two employees, Instadose Pharma is in the early stages of development.
What Products and Services Does INSD Offer?
- Cultivates medical-grade cannabis.
- Processes cannabis to extract cannabinoid oil.
- Distributes cannabinoid oil to pharmaceutical companies.
- Focuses on global distribution of medical cannabis products.
- Aims to provide high-quality cannabinoid oil for medical applications.
- Operates within the regulated medical cannabis industry.
- Seeks to expand its product portfolio and geographic reach.
How Does INSD Make Money?
- Generates revenue through the sale of medical-grade cannabinoid oil.
- Focuses on supplying pharmaceutical companies and researchers.
- Aims to establish long-term contracts with key customers.
What Industry Does INSD Operate In?
Instadose Pharma Corp. operates within the rapidly expanding medical cannabis industry. The industry is characterized by intense competition, evolving regulatory frameworks, and fluctuating prices. Instadose Pharma competes with both large pharmaceutical companies and smaller cannabis producers. The company's success depends on its ability to differentiate itself through product quality, regulatory compliance, and strategic partnerships. Companies like Aurora Cannabis and Canopy Growth are major players in the Canadian cannabis market, while others such as Arena Pharmaceuticals are focused on cannabinoid-based drug development.
Who Are INSD's Key Customers?
- Pharmaceutical companies developing cannabinoid-based therapies.
- Researchers studying the medical applications of cannabis.
- Distributors of medical cannabis products.
Company Profile
Instadose Pharma Corp. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Burlington, CA. The company is led by CEO Antonio Rocco Franchino. INSD has traded publicly since 2020.
Financial Health
Instadose Pharma Corp.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.65 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Its free cash flow yield is -0.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
INSD Valuation & Market Position
Relative to its peer group, INSD's quantitative score of 44/100 is below the peer average of 62/100.
INSD Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that leadership believes in the value of their product pipeline.
- Community sentiment has turned increasingly positive with discussions highlighting the potential of their innovative therapies and market positioning.
- Market developments around health and wellness have increased interest in companies like Instadose, aligning with broader trends in consumer health.
- Recent partnerships and collaborations have been announced, enhancing credibility and opening new avenues for growth.
Bear Case
- Despite positive sentiment, some analysts express caution over the competitive landscape, which may impact market share in the long term.
- Concerns about regulatory hurdles persist, as the pharmaceutical industry faces increasing scrutiny that could delay product launches.
- The volatility in market perception can lead to swings in sentiment, with some community members expressing skepticism about the company's ability to scale operations effectively.
- Recent press coverage has been mixed, with some reports highlighting potential challenges in execution that could dampen investor enthusiasm.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
INSD Latest News
No recent news available for INSD.
INSD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for INSD.
Price Targets
Wall Street price target analysis for INSD.
INSD MoonshotScore
What does this score mean?
The MoonshotScore rates INSD 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Antonio Rocco Franchino
CEO
Antonio Rocco Franchino is the CEO of Instadose Pharma Corp. His background includes managing the company's operations with a team of only two employees. Information regarding his prior experience, education, and specific credentials is not available. His leadership is focused on guiding the company through the complex regulatory landscape of the medical cannabis industry and establishing strategic partnerships to drive growth.
Track Record: Due to the limited information available, it is difficult to assess Antonio Rocco Franchino's track record. Key milestones under his leadership include navigating the initial stages of establishing Instadose Pharma Corp. in the medical cannabis market. Further information is needed to evaluate his strategic decisions and their impact on the company's performance.
INSD OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Instadose Pharma Corp. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and oversight, increasing the risk of fraud and manipulation.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in INSD.
- Low liquidity can lead to price volatility and difficulty in trading shares.
- The OTC Other tier carries a higher risk of fraud and manipulation.
- The company's small size and limited resources pose significant operational challenges.
- The evolving regulatory landscape of the cannabis industry adds uncertainty.
- Verify the company's registration and legal standing.
- Attempt to obtain and review any available financial statements.
- Assess the company's management team and their experience.
- Research the company's products and market position.
- Understand the regulatory environment in which the company operates.
- Evaluate the company's liquidity and trading volume.
- Consult with a financial advisor before investing.
- Focus on medical-grade cannabinoid oil suggests a commitment to quality.
- Based in Canada, which has a relatively well-established cannabis regulatory framework.
- Company has been in operation since 2017, indicating some level of operational stability.
INSD Healthcare Stock FAQ
What does the AI Score mean for INSD?
INSD holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Instadose Pharma Corp. focuses on the cultivation, processing, and global distribution of medical-grade cannabinoid oil. Founded in 2017, the company aims to establish a presence in the burgeoning …
What does Instadose Pharma Corp. do?
Instadose Pharma Corp. is involved in the cultivation, processing, and global distribution of medical-grade cannabinoid oil. The company aims to supply pharmaceutical companies and researchers with high-quality cannabinoid oil for various medical applications. The company's operations encompass the entire value chain, from growing and cultivation to processing and distribution.
What do analysts say about INSD stock?
As of March 18, 2026, there is no available analyst coverage for Instadose Pharma Corp. (INSD). The company's micro-cap status and OTC listing likely contribute to the lack of analyst attention.
What are the main risks for INSD?
Instadose Pharma Corp. faces several significant risks, including intense competition in the cannabis industry, fluctuating cannabinoid prices, and evolving regulatory frameworks. The company's small size and limited resources pose operational challenges, and its dependence on regulatory approvals creates uncertainty. Additionally, the OTC Other listing carries inherent risks related to liquidity, transparency, and potential for fraud. Investors should carefully consider these risks before investing in INSD.
What are the key factors to evaluate for INSD?
Instadose Pharma Corp. (INSD) holds an AI score of 44/100 (low). presents a high-risk, high-reward investment opportunity within the rapidly evolving medical cannabis sector. Not financial advice.
How frequently does INSD data refresh on this page?
INSD's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven INSD's recent stock price performance?
Instadose Pharma Corp. (INSD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on medical-grade cannabinoid oil. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider INSD overvalued or undervalued right now?
Instadose Pharma Corp. (INSD) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research INSD before investing?
Before investing in Instadose Pharma Corp. (INSD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on Instadose Pharma Corp.
- OTC Other listing indicates higher risk.
- AI analysis pending.